Matrix Laboratories Announces Appointment of Jagdish Dore’ as CEO
Matrix to Pursue Strategic Alternatives Including Potential Divestiture of Docpharma
Acquisition of residual holding in MCHEM GROUP OF COMPANIES, CHINA
Matrix executes definitive Agreement to acquire the residual holding of Mr.Mark Gao, the erstwhile promoter of Mchem Group of Companies
Matrix records net sales of Rs.4470 million and net profit of Rs.269 million for Q1 FY08
Matrix records net sales of Rs. 16,480 Million and Net Profit of Rs.763 Million for FYO7
Matrix Signs Agreement with Clinton Foundation for ARV Drugs
Matrix records net sales of Rs. 3,953 million in Q3FY07
Mylan Laboratories Completes Matrix Laboratories Transaction
Matrix records net sales of Rs.4422 million and net profit of Rs.338 million for Q1FY07
Matrix records net sales of Rs.11586 million and net profit of Rs.1992 million for FY-06
Clarification given to Times of India/Stock Exchanges
Matrix posts consolidated net profit of Rs. 100 Cr for Q3
Matrix to acquire controlling stake in Concord Biotech
Matrix plans preferential issue of 35 lakh equity shares at Rs.225 per share to the erstwhile promoters of Docpharma
Matrix posts, on consolidated basis, record sales of Rs. 291.58 crore and net profit of Rs. 43.69 crore for Q2
Matrix Laboratories completes the acquisition of Docpharma by obtaining 95.51% stake in the public takeover bid
Matrix enters Definitive Agreement for acquiring controlling stake in Mchem Group, China
Matrix and Aspen, South Africa, finalize Strategic business relationship
Matrix acquires 43 % stake in Explora, Switzerland
Matrix reports Rs.154 crore sales and Rs.25 crore
PAT for Q1 FY 05-06
Matrix and Strides Call-Off Merger Plans
Matrix secures WHO, Geneva, GMP certification
for two facilities
Matrix announces changes in Executive Management structure, Mr. Rajiv Malik to be the new CEO
Matrix Laboratories completes share purchase of controlling stake in Docpharma
Mr. Sanjeev Sethi joins as Sr. Vice President (Pharmaceuticals & Technical Services)
Matrix Laboratories Limited acquires controlling stake in Docpharma, Belgium
Matrix and Strides to Consider Merger
Matrix to pay 60% dividend, net at Rs. 130 cr for FY- 05
Matrix Labs' net sales at Rs 641 cr and
PAT at Rs 132 cr for FY 05
US FDA approval for Kazipally facility
Matrix and Aspen, South Africa, to form two JVs
Dr. Gopalan joins as Chief Scientific Officer (CSO)
Matrix to acquire major stake in MCHEM Pharma group, China
Hyderabad, March 23, 2005.
Matrix in strategic alliance with MCHEM of China
Hyderabad, February 7, 2005
Dr. Haseltine appointed as Chairman of Matrix Scientific Advisory Board (MSAB)
Hyderabad, January 27, 2005
Matrix Labs' Gross Sales at Rs 175 cr and
Net Profit at Rs 25.55 cr for Q3
Hyderabad, 22nd January 2005
Matrix Labs Purchases Finished Dosage Facility
Hyderabad, 19th January 2005
Matrix AGM approves Bonus issue and Stock split
Hyderabad, 16th December 2004
aRigen collaborates with Matrix for Drug Discovery Research
Tokyo, Nov 29, 2004
Matrix declares 1 : 1 Bonus issue
Matrix board meeting on October 26th
to consider
Q 2 financial results, Bonus issue
and stock split
Dr. C. Satyanarayana designated as
COO
11th October, 2004 at Hyderabad.
Q1 FY-05 financial results
17th
July, 2004 at Hyderabad.
FY- 04 financial results
24th
April, 2004 at Hyderabad.
Matrix Labs signs definitive
agreements with strategic investors
April 15th,
2004 at Hyderabad.
Matrix Labs to merge Vera Labs, Fine
Drugs and two other companies with itself.
Matrix Labs Bags USFDA Approval
The Economics Times -12th March, 2004
Lundbeck withdraws cases against
Matrix clients
TIMES NEWS NETWORK [ FRIDAY,
FEBRUARY 06, 2004 12:04:44 AM ]
Matrix Labs Q3 net at Rs 33 cr; sales
up 83%
Thursday 29th January 2004, Deccan
Chronicle, Hyderabad
Matrix to net Rs 607.5 cr via
preferential offer
Economic Times TIMES NEWS
NETWORK (Thursday , JANUARY 01, 2004 07:28:54 AM
)
Matrix sells 27.8% stake for Rs 607.5
crore
Business Standard, December 30, 2003
Matrix to set up two JVs in India,
Ireland
Business Standard, November 29, 2003
Matrix Labs plans 5 drug filings with
FDA
Business Standard, November 10, 2003
Matrix Labs signs agreement with
Clinton Foundation ( 1020 hrs ) Business Standard
October 24 2003
Matrix files 7 DMFs, bags US okay for
fluconazole.
Times News Network [ Saturday,
September 06, 2003 02:01:13 AM ]
Matrix bags US FDA nod for
fluconazole
Business Standard, July 28,
2003
Matrix adds new drugs for US generic
markets.
Times News Network [ Monday, July 28,
2003
09:20:49 AM ]
Matrix sews up Vorin, Medicorp
merger
May 19, 2003 (Business Standard)
Vorin, Medicorp Merger with Matrix
Okayed
Sunday, May 10, 2003 (Business
Line)
Matrix net at Rs.109 Crores
April
27, 2003 (Deccan Chronicle)
Matrix Labs net up 2330%
April 27,
2003 (Business Standard)
Matrix Q2 profit surges to Rs. 24
cr.
November 7, 2002 (The Hindu Business
Line)
| 
